{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T06:47:52Z","timestamp":1769237272497,"version":"3.49.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-32735-y","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T10:47:16Z","timestamp":1765968436000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development of a cost-effectiveness analysis model for Duchenne muscular dystrophy utilizing the national registry in Japan"],"prefix":"10.1038","volume":"16","author":[{"given":"Takuro","family":"Okada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Komaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takami","family":"Ishizuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari","family":"Oba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoko","family":"Hori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harumasa","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"32735_CR1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13023-017-0631-3","volume":"12","author":"S Ryder","year":"2017","unstructured":"Ryder, S. et al. The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review. Orphanet. J. Rare Dis. 12, 79 (2017).","journal-title":"Orphanet. J. Rare Dis."},{"key":"32735_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/8396429","volume":"2020","author":"S Han","year":"2020","unstructured":"Han, S. et al. Population-wide Duchenne muscular dystrophy carrier detection by CK and molecular testing. BioMed. Res. Int. 2020, 1\u201312 (2020).","journal-title":"BioMed. Res. Int."},{"key":"32735_CR3","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1136\/jmedgenet-2015-103387","volume":"53","author":"A Aartsma-Rus","year":"2016","unstructured":"Aartsma-Rus, A., Ginjaar, I. B. & Bushby, K. The importance of genetic diagnosis for Duchenne muscular dystrophy. J. Med. Genet. 53, 145\u2013151 (2016).","journal-title":"J. Med. Genet."},{"key":"32735_CR4","doi-asserted-by":"publisher","first-page":"950651","DOI":"10.3389\/fphar.2022.950651","volume":"13","author":"J Deng","year":"2022","unstructured":"Deng, J. et al. Drug development progress in Duchenne muscular dystrophy. Front. Pharmacol. 13, 950651 (2022).","journal-title":"Front. Pharmacol."},{"key":"32735_CR5","unstructured":"FDA. FDA approves first gene therapy for treatment of certain patients with Duchenne muscular dystrophy  (2023,  Aaccessed 10 Aug  2023.). https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-gene-therapy-treatment-certain-patients-duchenne-muscular-dystrophy."},{"key":"32735_CR6","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/humu.22758","volume":"36","author":"C Bladen","year":"2015","unstructured":"Bladen, C. et al. The TREAT-NMD DMD global database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum. Mutat. 36, 395\u2013402 (2015).","journal-title":"Hum. Mutat."},{"key":"32735_CR7","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.omtn.2018.09.017","volume":"13","author":"N Watanabe","year":"2018","unstructured":"Watanabe, N. et al. NS-065\/NCNP-01: an antisense oligonucleotide for potential treatment of exon 53 skipping in Duchenne muscular dystrophy. Mol. Ther. Nucleic Acids. 13, 442\u2013449 (2018).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"32735_CR8","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1002\/acn3.51235","volume":"7","author":"H Komaki","year":"2020","unstructured":"Komaki, H. et al. Viltolarsen in Japanese Duchenne muscular dystrophy patients: a phase 1\/2 study. Ann. Clin. Transl Neurol. 7, 2393\u20132408 (2020).","journal-title":"Ann. Clin. Transl Neurol."},{"key":"32735_CR9","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s40273-016-0461-5","volume":"35","author":"E Landfeldt","year":"2017","unstructured":"Landfeldt, E. et al. Economic evaluation in Duchenne muscular dystrophy: model frameworks for cost-effectiveness analysis. Pharmacoeconomics 35, 249\u2013258 (2017).","journal-title":"Pharmacoeconomics"},{"key":"32735_CR10","unstructured":"National Institute for Health and Care Excellence. Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene  (2016, accessed 10 Nov  2022). https:\/\/www.nice.org.uk\/guidance\/hst3?unlid=7891072072016831154657. ."},{"issue":"4","key":"32735_CR11","first-page":"361","volume":"26","author":"M Rind","year":"2020","unstructured":"Rind, M. & Steven, D. The effectiveness and value of Deflazacort and exon-skipping therapies for the management of Duchenne muscular dystrophy. J. Manag. Care Spec. Pharm. 26 (4), 361\u2013366 (2020).","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"32735_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1750-1172-8-60","volume":"8","author":"H Nakamura","year":"2013","unstructured":"Nakamura, H. et al. Characteristics of Japanese Duchenne and Becker muscular dystrophy patients in a novel Japanese National registry of muscular dystrophy (Remudy). Orphanet. J. Rare Dis. 8, 1\u20137 (2013).","journal-title":"Orphanet. J. Rare Dis."},{"key":"32735_CR13","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1002\/humu.22390","volume":"34","author":"C Bladen","year":"2013","unstructured":"Bladen, C. et al. The TREAT-NMD Duchenne muscular dystrophy registries: conception, design, and utilization by industry and academia. Hum. Mutat. 34, 1449\u20131457 (2013).","journal-title":"Hum. Mutat."},{"key":"32735_CR14","unstructured":"Japanese society of neurology. Duchenne muscular dystrophy clinical practice guidelines  (2014)."},{"key":"32735_CR15","first-page":"783","volume":"54","author":"T Saito","year":"2014","unstructured":"Saito, T., Tatara, K. & Kawai, M. Secular changes in disease status and cause of death of Duchenne muscular dystrophy patients in a Japanese muscular dystrophy inpatient facility (1999\u20132012). Clin. Neurol. 54, 783\u2013790 (2014).","journal-title":"Clin. Neurol."},{"key":"32735_CR16","first-page":"743","volume":"51","author":"T Matsumura","year":"2011","unstructured":"Matsumura, T. et al. Analysis of causes of death over time in patients with Duchenne muscular dystrophy. Clin. Neurol. 51, 743\u2013750 (2011).","journal-title":"Clin. Neurol."},{"key":"32735_CR17","unstructured":"National Institute of Public Health. Guidelines for analysis of cost-effectiveness evaluation in the central social insurance medical council, 3rd edition (2022)."},{"key":"32735_CR18","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1177\/0272989X211001859","volume":"41","author":"T Shiroiwa","year":"2021","unstructured":"Shiroiwa, T. et al. Valuation survey of EQ-5D-Y based on the international common protocol: development of a value set in Japan. Med. Decis. Mak. 41, 597\u2013606 (2021).","journal-title":"Med. Decis. Mak."},{"key":"32735_CR19","first-page":"47","volume":"64","author":"S Ikeda","year":"2015","unstructured":"Ikeda, S. et al. Developing a Japanese version of the EQ-5D-5L value set. Health Med. Sci. 64, 47\u201355 (2015).","journal-title":"Health Med. Sci."},{"key":"32735_CR20","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1007\/s00415-013-7104-y","volume":"260","author":"F Takeuchi","year":"2013","unstructured":"Takeuchi, F. et al. Prednisolone improves walking in Japanese Duchenne muscular dystrophy patients. J. Neurol. 260, 3023\u20133029 (2013).","journal-title":"J. Neurol."},{"key":"32735_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-014-0210-9","volume":"9","author":"O Schreiber-Katz","year":"2014","unstructured":"Schreiber-Katz, O. et al. Comparative cost of illness analysis and assessment of health care burden of Duchenne and Becker muscular dystrophies in Germany. Orphanet. J. Rare Dis. 9, 1\u201313 (2014).","journal-title":"Orphanet J. Rare Dis."},{"key":"32735_CR22","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1212\/WNL.0000000000000669","volume":"83","author":"E Landfeldt","year":"2014","unstructured":"Landfeldt, E. et al. The burden of Duchenne muscular dystrophy: an international, cross-sectional study. Neurol 83, 529\u2013536 (2014).","journal-title":"Neurol"},{"key":"32735_CR23","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1177\/0883073808314962","volume":"23","author":"L Ouyang","year":"2008","unstructured":"Ouyang, L., Grosse, S. D. & Kenneson, A. Health care utilization and expenditures for children and young adults with muscular dystrophy in a privately insured population. J. Child. Neurol. 23, 883\u2013888 (2008).","journal-title":"J. Child. Neurol."},{"key":"32735_CR24","doi-asserted-by":"crossref","unstructured":"Gamst-Klaussen, T. et al. Health state utility instruments compared: inquiring into nonlinearity across EQ-5D-5L, SF-6D, HUI-3 and 15D. Qual. Life Res. 2016, 1667\u20131678 (2016).","DOI":"10.1007\/s11136-015-1212-3"},{"key":"32735_CR25","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1177\/0272989X15578127","volume":"36","author":"G Chen","year":"2016","unstructured":"Chen, G. et al. Mapping between 6 multi-attribute utility instruments. Med. Decis. Mak. 36, 160\u2013175 (2016).","journal-title":"Med. Decis. Mak."},{"key":"32735_CR26","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/0272989X09347016","volume":"30","author":"DG Fryback","year":"2010","unstructured":"Fryback, D. G. et al. Comparison of 5 health-related quality-of-life indexes using item response theory analysis. Med. Decis. Mak. 30, 5\u201315 (2010).","journal-title":"Med. Decis. Mak."},{"key":"32735_CR27","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1002\/hec.1505","volume":"19","author":"J Seymour","year":"2020","unstructured":"Seymour, J. et al. Shedding new light onto the ceiling and floor? A quantile regression approach to compare EQ-5D and SF-6D responses. Health Econ. 19, 683\u2013696 (2020).","journal-title":"Health Econ."},{"key":"32735_CR28","unstructured":"AQOL Multi-Instrument Comparison study transformations \u201cMapping onto EQ5D-5L\u201d (2022, accessed 9 Dec  2022). http:\/\/aqol.com.au\/MIC\/MIC-Mapping-Equations-EQ5D.pdf."},{"key":"32735_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12955-016-0455-1","volume":"14","author":"I Khan","year":"2016","unstructured":"Khan, I. et al. Comparing the mapping between EQ-5D-5L, EQ-5D-3L and the EORTC-QLQ-C30 in non-small cell lung cancer patients. Health Qual. Life Outcomes. 14, 1\u201315 (2016).","journal-title":"Health Qual. Life Outcomes"},{"key":"32735_CR30","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40273-020-00893-8","volume":"38","author":"AJ Thompson","year":"2020","unstructured":"Thompson, A. J. & Turner, A. J. A comparison of the EQ-5D-3L and EQ-5D-5L. Pharmacoeconomics 38, 575\u2013591 (2020).","journal-title":"Pharmacoeconomics"},{"key":"32735_CR31","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1212\/WNL.0000000000001336","volume":"84","author":"CM Bann","year":"2015","unstructured":"Bann, C. M. et al. Measuring quality of life in muscular dystrophy. Neurol 84, 1034\u20131042 (2015).","journal-title":"Neurol"},{"key":"32735_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12955-020-01511-z","volume":"18","author":"PA Powell","year":"2020","unstructured":"Powell, P. A. et al. Measuring quality of life in Duchenne muscular dystrophy: a systematic review of the content and structural validity of commonly used instruments. Health Qual. Life Outcomes. 18, 1\u201326 (2020).","journal-title":"Health Qual. Life Outcomes"},{"key":"32735_CR33","first-page":"2438","volume":"96","author":"PA Powell","year":"2021","unstructured":"Powell, P. A. et al. Development of a new quality of life measure for Duchenne muscular dystrophy using mixed methods: the DMD-QoL. Neurol 96, 2438\u20132450 (2021).","journal-title":"Neurol"},{"key":"32735_CR34","first-page":"14","volume":"49","author":"T Nakajima","year":"2015","unstructured":"Nakajima, T. Quality of life assessment of patients with neurological incurable diseases. J. Occup. Ther. 49, 14\u201319 (2015).","journal-title":"J. Occup. Ther."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32735-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32735-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32735-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T01:05:05Z","timestamp":1769216705000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32735-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["32735"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-32735-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"assertion":[{"value":"15 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Mr. Okada is currently an employee of Astellas Pharma Inc, but from the start to the end of the study, he was affiliated with Keio University, and thus has no conflicts of interest to disclose. Dr. Komaki reported receiving grants from Taiho, Nippon Shinyaku, Chugai, Sanofi, Pfizer Japan, Daiichi Sankyo, and PTC Therapeutics; consulting fees from PTC Therapeutics, Astellas, Daiichi Sankyo, and Sarepta Therapeutics; and payment for educational events from Chugai, Biogen, Sanofi, Novartis, and Nippon Shinyaku. Dr. Oba reported receiving payments for educational events from Pfizer Japan, Astra Zeneca, SAS Japan, and EP-SOGO. Dr. Nakamura reported receiving grants from Pfizer Japan, Nippon Shinyaku, Daiichi Sankyo, and Astellas; and consulting fee from Nippon Shinyaku. Dr. Ishizuka, and Dr. Hori reported no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The patients have provided written informed consent for the publication of the collected data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All methods were performed in accordance with relevant guidelines and regulations. The study that analyzed the Remudy data was approved by the ethics committee of the National Center of the Neurology and Psychiatry (NCNP). (No. A2022-001) The questionnaire survey on QOL of DMD patients was approved by the ethics committee of both NCNP and Keio University Faculty of Pharmacy. (No. B2022-023, 220808)","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical considerations"}},{"value":"The patients have provided written informed consent for participating studies.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"2883"}}